Regeneron Pharmaceuticals | REGN - Betriebsaufwand

Aktienkurs
702.28
Täglich Wechseln
-6.93 -0.98%
Monatlich
-7.96%
Jährlich
25.74%
Q2 Prognose
686.83




Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Agenus USD 19.81M 293.94M 2025-12
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Astellas Pharma JPY 489.36B 52.69B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
J&J USD 17.44B 1.53B 2026-03
Kyowa Hakko Kirin JPY 109.02B 16.08B 2025-12
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.29B 507M 2026-03
Novartis USD 9.8B 23M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 10.71B 1.32B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03